I
n Boston's thriving Seaport District, a hub for life science innovation, Phase 3 Real Estate Partners has secured a major lease agreement with CytoTronics, a pioneering biotech firm. The company will occupy 14,000 square feet at GENESIS 12 Farnsworth, a cutting-edge facility tailored to the needs of high-growth startups.

    For CytoTronics, this new location represents a strategic expansion opportunity, providing access to top talent and the necessary resources for growth. "We needed a space that would support our rapid expansion while fostering an environment conducive to innovation," said Jeffrey Abbott, Co-founder and CEO. "GENESIS 12 Farnsworth offers us the flexibility and infrastructure we require to take our research to the next level."

    CytoTronics' flagship Pixel platform integrates semiconductors with standard microplates, enabling multi-modal insights at single-cell resolution. This technology has far-reaching applications in cell biology research, drug development, and pharmaceutical manufacturing.

    The lease signing underscores the Seaport's status as a magnet for biotechnology firms seeking cutting-edge infrastructure and proximity to leading academic and medical institutions. "We're committed to supporting the life science community by providing best-in-class environments that empower innovation," said Morgan Weinstein, Executive Vice President at P3RE. "We're thrilled to welcome CytoTronics to GENESIS 12 Farnsworth and look forward to their continued growth and success."

    GENESIS 12 Farnsworth offers premium amenities and adaptable lab configurations, making it an ideal location for startups and established firms alike in the competitive biotech landscape. The transaction was brokered by CBRE, representing the landlord.

    This latest milestone further solidifies P3RE's reputation as a top-tier developer in the life sciences sector, delivering dynamic spaces that enable companies to push the boundaries of scientific innovation.